Table 3.
Predictive factors of radiological sequelae at follow-up in patients hospitalized for SARS-COV-2-related pneumonia.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| OR (95% IC) | p | OR (95% IC) | p | |
| Sex | ||||
| Female Male |
Ref. 1.87 (0.95—3.69) |
- 0.07 |
- - |
- - |
| Age—years | ||||
| <59 ≥59 |
Ref. 2.99 (1.47–6.08) |
- 0.002 |
Ref. 0.81 (0.10–6.39) |
- 0.84 |
| BMI—(kg/m2) | ||||
| <26 ≥26 |
Ref. 0.80 (0.41–1.58) |
- 0.52 |
- - |
- - |
| Smoking history–pack–years | ||||
| = 0 >0 |
Ref. 1.56 (0.79–3.10) |
- 0.19 |
- - |
- - |
| Hospitalization—days | ||||
| <9 ≥9 |
Ref. 4.77 (2.15–10.5) |
- <0.0001 |
Ref. 12.77 (0.65–248.8) |
- 0.09 |
| PiO2/FiO2 at admission | ||||
| <314 ≥314 |
Ref. 0.33 (0.13–0.80) |
- 0.01 |
Ref. 1.24 (0.13–11.46) |
- 0.84 |
| CVD | ||||
| No Yes |
Ref. 1.95 (1.00–3.80) |
- 0.04 |
Ref. 1.40 (0.15–12.48) |
- 0.76 |
| Respiratory diseases | ||||
| No Yes |
Ref. 1.20 (0.52–2.77) |
- 0.65 |
- - |
- - |
| Autoimmune diseases | ||||
| No Yes |
Ref. 1.94 (0.87–4.32) |
- 0.11 |
- - |
- - |
| Metabolic diseases | ||||
| No Yes |
Ref. 1.42 (0.73–2.74) |
- 0.29 |
- - |
- - |
| Oncologic diseases | ||||
| No Yes |
Ref. 2.01 (0.80–5.01) |
- 0.13 |
- - |
- - |
| Degree of care | ||||
| Low High |
Ref. 2.98 (1.49–5.95) |
- 0.002 |
Ref. 1.35 (0.13–13.12) |
- 0.79 |
| FiO2 max—% | ||||
| <28 ≥28 |
Ref. 3.25 (1.54–6.80) |
- 0.002 |
Ref. 1.01 (0.07–16.2) |
- 0.99 |
| Alveolar score HRCT0—% | ||||
| <7 ≥7 |
Ref. 4.0 (1.33–11.98) |
- 0.01 |
Ref. 0.74 (0.09–5.99) |
- 0.78 |
| Consolidations HRCT0—% | ||||
| <0.8 ≥0.8 |
Ref. 6.29 (1.66–23.87) |
- 0.007 |
Ref. 20.6 (1.40–301.2) |
- 0.02 |
| Interstitial score HRCT0—% | ||||
| <1.4 ≥1.4 |
Ref. 41.2 (5.1–331.8) |
- <0.0001 |
Ref. 23.0 (1.40–377.2) |
- 0.02 |
| Hidroxicloroquina | ||||
| Yes No |
Ref 2.66 (1.17–6.07) | 0.02 | Ref 1.26 (0.18–8.82) | 0.80 |
| Azithromycin | ||||
| Yes No |
Ref. 0.76 (0.39–1.47) |
- 0.41 |
- - |
- - |
| Ceftriaxone | ||||
| Yes No |
Ref. 1.74 (0.89–3.40) |
- 0.10 |
- - |
- - |
| Other antibiotics | ||||
| Yes No |
Ref. 3.72 (1.88–7.34) |
- <0.0001 |
Ref. 4.87 (0.52–45.7) |
- 0.16 |
| Lopinovir/Ritonavir | ||||
| Yes No |
Ref. 1.49 (0.75–2.94) |
- 0.24 |
- - |
- - |
| Remdesevir | ||||
| Yes No |
Ref. 3.03 (1.08–8.49) |
- 0.03 |
Ref. 12.5 (0.41–3.85) |
- 0.14 |
| Glutathione | ||||
| Yes No |
Ref. 0.22 (0.09–1.75) |
- 0.15 |
- - |
- - |
| Tocilizumab | ||||
| Yes No |
Ref. 2.93 (1.12–7.69) |
- 0.02 |
Ref. 0.6 (0.03–11.1) |
- 0.73 |
| Plasma | ||||
| Yes No |
Ref. 1.49 (0.37–5.86) |
- 0.56 |
- - |
- - |
| Steroids during hospitalization | ||||
| Yes No |
Ref. 2.04 (1.05–3.99) |
- 0.03 |
Ref. 1.04 (0.09 – 11.6) |
- 0.97 |
Values are expressed as OR (95%CI). Logistic regression analysis was used to determine the relationship of clinical data with radiological sequelae at follow-up.